MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer

AbbVie today announced that the UK Medicines and Healthcare products Regulatory Agency has granted conditional Marketing Authorisation for Tepkinly® (epcoritamab) as a monotherapy for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), after two or more systemic therapies.

Related Keywords

United Kingdom ,Nottingham ,Great Britain ,Belinda Byrne ,Lily Ramsey ,Chris Fox ,University Hospitals ,Regulatory Agency ,University Of Nottingham ,School Of Medicine ,United Kingdom Medicines ,Marketing Authorisation ,Marketing Authorization ,Professor Chris Fox ,Honorary Consultant Haematologist ,Medical Director ,Abbvie United ,Blood ,Blood Cancer ,Dancer ,Ntibody ,B Cell ,Bispecific Antibody ,Fell ,Healthcare ,Immune System ,Lymphoma ,Yndrome ,White Blood Cell ,